ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2004
In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Yeast-secreted compounds with antifungal activity-screening, genetic parts, biosynthetic pathways, and regulation.FEMS yeast research · 2025Review
- Antifungal Resistance in Cryptococcal Infections.Pathogens (Basel, Switzerland) · 2024Review
- Cryptococcus neoformans, a global threat to human health.Infectious diseases of poverty · 2023Review
- Lack of Association between YEASTONE Antifungal Susceptibility Tests and Clinical Outcomes ofJournal of fungi (Basel, Switzerland) · 2023Article
- A Peptide from Budding Yeast GAPDH Serves as a Promising Antifungal against Cryptococcus neoformans.Microbiology spectrum · 2022Article
- Amphotericin B and Other Polyenes-Discovery, Clinical Use, Mode of Action and Drug Resistance.Journal of fungi (Basel, Switzerland) · 2020Review
- Article
- Molecular typing of clinical isolates of Cryptococcus neoformans/Cryptococcus gattii species complex from Northeast Mexico.Folia microbiologica · 2016Article
- Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal.The Journal of antimicrobial chemotherapy · 2013Review
- Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.Antimicrobial agents and chemotherapy · 2012Article
- Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2012Article
- Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility.Diagnostic microbiology and infectious disease · 2012Article
- Chemosensitization as a means to augment commercial antifungal agents.Frontiers in microbiology · 2012Article
- Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007-2008.Antimicrobial agents and chemotherapy · 2011Article
- Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.Journal of clinical microbiology · 2009Article
- Voriconazole in the management of nosocomial invasive fungal infections.Therapeutics and clinical risk management · 2006Article
- Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).Journal of clinical microbiology · 2005Article
- Synergic effect of simvastatin in combination with amphotericin B against environmental strains of Cryptococcus neoformans from northeastern Brazil: a prospective experimental study.Sao Paulo medical journal = Revista paulista de medicinaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In order to determine the potential role that various antifungal agents might have in the management of cryptococcosis in tropical areas, the in vitro susceptibility of Cryptococcus neoformans isolates from Africa ( n=52) and Cambodia ( n=110) to three antifungal agents (amphotericin B, fluconazole and voriconazole) were compared using the E-test method. The results of this study (i) confirm the value of the E-test for testing the in vitro susceptibility of C. neoformans towards voriconazole; (ii) provide the first evidence demonstrating good activity of amphotericin B, fluconazole and voriconazole against Cambodian isolates; and (iii) show there are differences in susceptibility between African and Asian C. neoformans isolates, with Cambodian isolates appearing less susceptible to the agents tested but with amphotericin B maintaining good activity.
Indexed as
Identifiers
15141336What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.